These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34659627)

  • 1. Dogmas, challenges, and promises in phase III allergen immunotherapy studies.
    De Kam PJ; Kramer MF; Shamji MH; Oluwayi K; Heath MD; Jensen-Jarolim E; Berger MH; Berger UE; Graessel A; Sellwood F; Zielen S; Vogelberg C; Zieglmayer P; Mösges R; Klimek L; DuBuske LM; Shreffler WG; Bernstein JA; Kündig TM; Skinner MA
    World Allergy Organ J; 2021 Sep; 14(9):100578. PubMed ID: 34659627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy of allergies: current status].
    Mahler V; Kleine-Tebbe J; Vieths S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1341-1356. PubMed ID: 33140209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allergen immunotherapy phase II trials: Challenges in dose finding.
    Kleine-Tebbe J; Kaul S; Mösges R
    Allergol Select; 2019; 3(1):1-8. PubMed ID: 32176223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy.
    Pfaar O; Zieglmayer P
    Clin Transl Allergy; 2020; 10():33. PubMed ID: 32742636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in allergen immunotherapy: 2019 and beyond.
    Pfaar O; Agache I; de Blay F; Bonini S; Chaker AM; Durham SR; Gawlik R; Hellings PW; Jutel M; Kleine-Tebbe J; Klimek L; Kopp MV; Nandy A; Rabin RL; van Ree R; Renz H; Roberts G; Salapatek AM; Schmidt-Weber CB; Shamji MH; Sturm GJ; Virchow JC; Wahn U; Willers C; Zieglmayer P; Akdis CA
    Allergy; 2019 Dec; 74 Suppl 108():3-25. PubMed ID: 31872476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding differences in allergen immunotherapy products and practices in North America and Europe.
    Mahler V; Esch RE; Kleine-Tebbe J; Lavery WJ; Plunkett G; Vieths S; Bernstein DI
    J Allergy Clin Immunol; 2019 Mar; 143(3):813-828. PubMed ID: 30850069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs.
    Pfaar O; Gerth van Wijk R; Klimek L; Bousquet J; Creticos PS
    Clin Transl Allergy; 2020; 10():11. PubMed ID: 32346471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products.
    Bonertz A; Roberts GC; Hoefnagel M; Timon M; Slater JE; Rabin RL; Bridgewater J; Pini C; Pfaar O; Akdis C; Goldstein J; Poulsen LK; van Ree R; Rhyner C; Barber D; Palomares O; Sheikh A; Pawankar R; Hamerlijnk D; Klimek L; Agache I; Angier E; Casale T; Fernandez-Rivas M; Halken S; Jutel M; Lau S; Pajno G; Sturm G; Varga EM; Gerth van Wijk R; Bonini S; Muraro A; Vieths S
    Allergy; 2018 Jan; 73(1):64-76. PubMed ID: 28771830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for subcutaneous versus sublingual immunotherapy.
    Larenas-Linnemann D
    Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):588-95. PubMed ID: 26485098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of adjuvants in allergen-immunotherapy.
    Klimek L; Schmidt-Weber CB; Kramer MF; Skinner MA; Heath MD
    Expert Rev Clin Immunol; 2017 Jun; 13(6):599-610. PubMed ID: 28162007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study.
    Reiber R; Keller M; Keller W; Wolf H; Schnitker J; Wüstenberg E
    Clin Transl Allergy; 2015; 6():9. PubMed ID: 26958338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in allergen immunotherapy: current concepts and future needs.
    Pfaar O; Alvaro M; Cardona V; Hamelmann E; Mösges R; Kleine-Tebbe J
    Allergy; 2018 Sep; 73(9):1775-1783. PubMed ID: 29446469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State of the Art: Development of a Sublingual Allergy Immunotherapy Tablet for Allergic Rhinitis in Japan.
    Ohashi-Doi K; Lund K; Mitobe Y; Okamiya K
    Biol Pharm Bull; 2020; 43(1):41-48. PubMed ID: 31902930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of allergen immunotherapy.
    Şahin E; Bafaqeeh SA; Güven SG; Çetinkaya EA; Muluk NB; Coşkun ZO; Lopatin A; Kar M; Pinarbasli MO; Cingi C
    Am J Rhinol Allergy; 2016 Sep; 30(5):1-3. PubMed ID: 27658024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience.
    Jensen-Jarolim E; Roth-Walter F; Jordakieva G; Pali-Schöll I
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1780-1789. PubMed ID: 33753052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence.
    Martignago I; Incorvaia C; Ridolo E
    Clin Mol Allergy; 2017; 15():13. PubMed ID: 28638279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.